These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9179398)

  • 1. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo.
    Lewis EJ; Bishop J; Bottomley KM; Bradshaw D; Brewster M; Broadhurst MJ; Brown PA; Budd JM; Elliott L; Greenham AK; Johnson WH; Nixon JS; Rose F; Sutton B; Wilson K
    Br J Pharmacol; 1997 Jun; 121(3):540-6. PubMed ID: 9179398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitro.
    Nixon JS; Bottomley KM; Broadhurst MJ; Brown PA; Johnson WH; Lawton G; Marley J; Sedgwick AD; Wilkinson SE
    Int J Tissue React; 1991; 13(5):237-41. PubMed ID: 1666894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase.
    Billinghurst RC; Wu W; Ionescu M; Reiner A; Dahlberg L; Chen J; van Wart H; Poole AR
    Arthritis Rheum; 2000 Mar; 43(3):664-72. PubMed ID: 10728761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of cartilage degradation and changes in physical properties induced by IL-1beta and retinoic acid using matrix metalloproteinase inhibitors.
    Bonassar LJ; Sandy JD; Lark MW; Plaas AH; Frank EH; Grodzinsky AJ
    Arch Biochem Biophys; 1997 Aug; 344(2):404-12. PubMed ID: 9264555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esculetin (dihydroxycoumarin) inhibits the production of matrix metalloproteinases in cartilage explants, and oral administration of its prodrug, CPA-926, suppresses cartilage destruction in rabbit experimental osteoarthritis.
    Yamada H; Watanabe K; Saito T; Hayashi H; Niitani Y; Kikuchi T; Ito A; Fujikawa K; Lohmander LS
    J Rheumatol; 1999 Mar; 26(3):654-62. PubMed ID: 10090178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.
    Esser CK; Bugianesi RL; Caldwell CG; Chapman KT; Durette PL; Girotra NN; Kopka IE; Lanza TJ; Levorse DA; MacCoss M; Owens KA; Ponpipom MM; Simeone JP; Harrison RK; Niedzwiecki L; Becker JW; Marcy AI; Axel MG; Christen AJ; McDonnell J; Moore VL; Olszewski JM; Saphos C; Visco DM; Hagmann WK
    J Med Chem; 1997 Mar; 40(6):1026-40. PubMed ID: 9083493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinoic acid-induced type II collagen degradation does not correlate with matrix metalloproteinase activity in cartilage explant cultures.
    Price JS; Wang-Weigand S; Bohne R; Kozaci LD; Hollander AP
    Arthritis Rheum; 1999 Jan; 42(1):137-47. PubMed ID: 9920024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
    Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
    Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.
    Monovich LG; Tommasi RA; Fujimoto RA; Blancuzzi V; Clark K; Cornell WD; Doti R; Doughty J; Fang J; Farley D; Fitt J; Ganu V; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Parker DT; Melton R; O'Byrne E; Pastor G; Pellas T; Quadros E; Reel N; Roland DM; Sakane Y; Singh H; Skiles J; Somers J; Toscano K; Wigg A; Zhou S; Zhu L; Shieh WC; Xue S; McQuire LW
    J Med Chem; 2009 Jun; 52(11):3523-38. PubMed ID: 19422229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of potent and selective MMP-13 inhibitors.
    Wu J; Rush TS; Hotchandani R; Du X; Geck M; Collins E; Xu ZB; Skotnicki J; Levin JI; Lovering FE
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4105-9. PubMed ID: 16005220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vanadate, an inhibitor of stromelysin and collagenase expression, suppresses collagen induced arthritis.
    Oliver SJ; Firestein GS; Arsenault L; Cruz TF; Cheng TP; Banquerigo ML; Boyle DL; Brahn E
    J Rheumatol; 2007 Sep; 34(9):1802-9. PubMed ID: 17696279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in a guinea pig model of osteoarthritis.
    Sabatini M; Lesur C; Thomas M; Chomel A; Anract P; de Nanteuil G; Pastoureau P
    Arthritis Rheum; 2005 Jan; 52(1):171-80. PubMed ID: 15641085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fibronectin fragment induces type II collagen degradation by collagenase through an interleukin-1-mediated pathway.
    Yasuda T; Poole AR
    Arthritis Rheum; 2002 Jan; 46(1):138-48. PubMed ID: 11817586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinoic acid combines with interleukin-1 to promote the degradation of collagen from bovine nasal cartilage: matrix metalloproteinases-1 and -13 are involved in cartilage collagen breakdown.
    Shingleton WD; Ellis AJ; Rowan AD; Cawston TE
    J Cell Biochem; 2000 Sep; 79(4):519-31. PubMed ID: 10996843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits.
    MacPherson LJ; Bayburt EK; Capparelli MP; Carroll BJ; Goldstein R; Justice MR; Zhu L; Hu S; Melton RA; Fryer L; Goldberg RL; Doughty JR; Spirito S; Blancuzzi V; Wilson D; O'Byrne EM; Ganu V; Parker DT
    J Med Chem; 1997 Aug; 40(16):2525-32. PubMed ID: 9258358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of procollagenases is a key control point in cartilage collagen degradation: interaction of serine and metalloproteinase pathways.
    Milner JM; Elliott SF; Cawston TE
    Arthritis Rheum; 2001 Sep; 44(9):2084-96. PubMed ID: 11592371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and mechanism of action of KHBJ-9B, a new herbal medicine, and its major compound triterpenoids in human cartilage culture and in a rabbit model of collagenase-induced osteoarthritis.
    Huh JE; Baek YH; Ryu SR; Lee JD; Choi DY; Park DS
    Int Immunopharmacol; 2009 Feb; 9(2):230-40. PubMed ID: 19100343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stromelysin 1, neutrophil collagenase, and collagenase 3 do not play major roles in a model of chondrocyte mediated cartilage breakdown.
    Kozaci LD; Brown CJ; Adcocks C; Galloway A; Hollander AP; Buttle DJ
    Mol Pathol; 1998 Oct; 51(5):282-6. PubMed ID: 10193524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1).
    Dahlberg L; Billinghurst RC; Manner P; Nelson F; Webb G; Ionescu M; Reiner A; Tanzer M; Zukor D; Chen J; van Wart HE; Poole AR
    Arthritis Rheum; 2000 Mar; 43(3):673-82. PubMed ID: 10728762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.